A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →. With Regeneron Pharmaceuticals.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
392actual
Sites
17
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-24 | actual | When the study began enrolling |
| Primary completion | 2025-12-15 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-02 | actual | The whole study's end, after follow-up |
| First posted | 2024-04-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity
Interventions
- Drug: Tirzepatide — also filed as LY3298176
- Drug: Mibavademab — also filed as REGN4461
- Drug: Tirzepatide-Placebo
- Drug: Mibavademab-Placebo
Primary outcome
what the primary-completion date above is the date OFMean Percent Change from Baseline in Body Weight
measured Baseline, Week 48
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed